Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol
Jordana B. Cohen(University of Pennsylvania), Julio A. Chirinos(The Lundquist Institute), Daniel Edmonston(Duke University), Alejandro Barbagelata(Favaloro Foundation), C. Medina(Hospital Nacional Cayetano Heredia), Tara I. Chang, Tiffany Sharkoski(Hospital of the University of Pennsylvania), Preethi William(University of Arizona), Nelson R. Rosado‐Santander(Hospital Nacional Cayetano Heredia), Carlos Augusto Castro‐Callirgos(Instituto Nacional de Salud del Niño), Jaime Andrade‐Villanueva(Hospital Civil de Guadalajara), Jesse Chittams, Nicolás Renna(University of Mendoza), Eduardo F Bernales-Salas(Hospital Nacional Cayetano Heredia), James Brian Byrd(University of Michigan), Juan E. Rodriguez‐Mori(Instituto Nacional de Salud del Niño), Mirko Villavicencio, Jonas Spaak(Karolinska University Hospital), Nancy K. Sweitzer(National Heart Lung and Blood Institute), Michael O. Harhay(University College London), Vicente Corrales‐Medina(University of Ottawa), Karen E. Tupayachi‐Venero, Carlos E. Alfonso(University of Miami), Renzo Valdivia, Thomas C. Hanff(University of Pennsylvania), Charles R. Vasquez(Hospital of the University of Pennsylvania), Johanna Coacalla
Cited by 19
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.2k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association
|Circulation|2019|1.3k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial
|Circulation|2014|1k
Chronic Kidney Disease and Coronary Artery Disease
|Journal of the American College of Cardiology|2019|716